title: Neuroparalysis and oxime efficacy in organophosphate poisoning: a study of butyrylcholinesterase.
abstract: The temporal profile of butyrylcholinesterase (BuChE) and in vitro pralidoxime-reactivated BuChE was studied in a cohort of 25 organophosphate-poisoned patients to examine their relationship to the development of intermediate syndrome and to understand reasons for lack of efficacy of oxime treatment. The clinical severity of poisoning (assessed by the Namba Scale) correlated significantly with the severity of intermediate syndrome. BuChE activity increased significantly over time and showed significant relationship to muscle power. The temporal profile of the enzyme was correlated to the clinical severity of poisoning. Reactivation potentials of BuChE (the difference between oxime-reactivated and -unreactivated enzyme activity) declined significantly with time after organophosphate ingestion. The reactivation potential of the enzyme at admission decreased significantly with increasing severity of poisoning and was lower in patients who developed intermediate syndrome. Patients who received oxime prior to hospitalization had a higher rate of intermediate syndrome and lower levels of BuChE at admission than those who had not. The study suggests that (i) BuChE reflects the clinical course of poisoning, confirming earlier studies; (ii) intermediate syndrome may be associated with a persistent inhibition of BuChE; and (iii) the lack of oxime efficacy in our patients maybe due to their severity of poisoning and the timing of oxime treatment.
authors.affiliation: Department of Medicine, Christian Medical College and Hospital, Vellore, Tamil Nadu, India.
authors.forename: S
authors.initials: S
authors.lastname: Khan
authors.forename: R
authors.initials: R
authors.lastname: Hemalatha
authors.forename: L
authors.initials: L
authors.lastname: Jeyaseelan
authors.forename: A
authors.initials: A
authors.lastname: Oommen
authors.forename: A
authors.initials: A
authors.lastname: Zachariah
mesh_terms: D000328:Adult; D000931:Antidotes / Q000008:administration & dosage; D002091:Butyrylcholinesterase / Q000378:metabolism / Q000506:poisoning*; D015331:Cohort Studies; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007306:Insecticides / Q000506:poisoning*; D008297:Male; D009132:Muscles / Q000473:pathology; D009943:Organophosphorus Compounds; D010091:Oximes / Q000627:therapeutic use*; D011041:Poisoning / Q000175:diagnosis / Q000378:metabolism / Q000628:therapy*; D011220:Pralidoxime Compounds / Q000627:therapeutic use*; D012720:Severity of Illness Index; D013405:Suicide
chemical_list: D000931:Antidotes; D007306:Insecticides; D009943:Organophosphorus Compounds; D010091:Oximes; D011220:Pralidoxime Compounds; D002091:Butyrylcholinesterase; C028797:pralidoxime